United States
Germany
Japan
United Kingdom
China
Scramblase 1 (PLSCR1) (NM_021105) Human Tagged ORF Clone Lentiviral Particle
CAT＃: RC207485L3V
- LentiORF®
-
Lenti ORF particles, PLSCR1 (Myc-DDK tagged) - Human phospholipid scramblase 1 (PLSCR1), 200ul, >10^7 TU/mL
Need custom lentivirus service?
Get a free quote
CNY 8,170.00
货期*
详询
规格
Product images
经常一起买 (3)
Specifications
| Product Data | |
| Product Name | Scramblase 1 (PLSCR1) (NM_021105) Human Tagged ORF Clone Lentiviral Particle |
| Synonyms | MMTRA1B |
| Vector | pLenti-C-Myc-DDK-P2A-Puro |
| ACCN | NM_021105 |
| ORF Size | 954 bp |
| Sequence Data |
The ORF insert of this clone is exactly the same as(RC207485).
|
| OTI Disclaimer | The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info |
| OTI Annotation | This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. |
| Reference Data | |
| RefSeq | NM_021105.1 |
| RefSeq Size | 2228 bp |
| RefSeq ORF | 957 bp |
| Locus ID | 5359 |
| Domains | Scramblase |
| Protein Families | Druggable Genome, Stem cell - Pluripotency |
| MW | 35 kDa |
| Gene Summary | May mediate accelerated ATP-independent bidirectional transbilayer migration of phospholipids upon binding calcium ions that results in a loss of phospholipid asymmetry in the plasma membrane. May play a central role in the initiation of fibrin clot formation, in the activation of mast cells and in the recognition of apoptotic and injured cells by the reticuloendothelial system.[UniProtKB/Swiss-Prot Function] |
Documents
| Product Manuals |
| FAQs |
| SDS |
Resources
You may also need
其它Scramblase 1产品
Customer
Reviews
Loading...
